Clinical Genomics Laboratory

Publications

Found 14 results
Author Title Type [ Year(Asc)]
Filters: First Letter Of Last Name is L  [Clear All Filters]
2019
Schwartz GW, Manning B, Zhou Y, Velu P, Bigdeli A, Astles R, Lehman AW, Morrissette JJD, Perl AE, Li M et al..  2019.  Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors.. Clin Cancer Res. 25(2):573-583.
Schwartz GW, Manning B, Zhou Y, Velu P, Bigdeli A, Astles R, Lehman AW, Morrissette JJD, Perl AE, Li M et al..  2019.  Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors.. Clin Cancer Res. 25(2):573-583.
Velu PD, Perl AE, Luger SM, Bagg A, Morrissette JJD.  2019.  Longitudinal targeted next-generation sequencing in a patient with acute myeloid leukaemia.. Br J Haematol. 186(6):801.
Xing D, Liu Y, Park HJin, Baek I, Tran H, Cheang G, Novo J, Dillon J, Matoso A, Farmer E et al..  2019.  Recurrent genetic alterations and biomarker expression in primary and metastatic squamous cell carcinomas of the vulva.. Hum Pathol. 92:67-80.
Xing D, Liu Y, Park HJin, Baek I, Tran H, Cheang G, Novo J, Dillon J, Matoso A, Farmer E et al..  2019.  Recurrent genetic alterations and biomarker expression in primary and metastatic squamous cell carcinomas of the vulva.. Hum Pathol. 92:67-80.
Nam AS, Kim K-T, Chaligne R, Izzo F, Ang C, Taylor J, Myers RM, Abu-Zeinah G, Brand R, Omans ND et al..  2019.  Somatic mutations and cell identity linked by Genotyping of Transcriptomes.. Nature. 571(7765):355-360.
Chaligne R, Nam AS, Landau DA.  2019.  TARGET-seq Takes Aim at Cancer Evolution through Multi-omics Single-Cell Genotyping and Transcriptomics.. Mol Cell. 73(6):1092-1094.
2018
Rosenbaum JN, Bloom R, Forys JT, Hiken J, Armstrong JR, Branson J, McNulty S, Velu PD, Pepin K, Abel H et al..  2018.  Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer.. Mod Pathol. 31(5):791-808.
2016
Rennert H, Eng K, Zhang T, Tan A, Xiang J, Romanel A, Kim R, Tam W, Liu Y-C, Bhinder B et al..  2016.  Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care.. NPJ Genom Med. 1
Kluk MJ, R Lindsley C, Aster JC, Lindeman NI, Szeto D, Hall D, Kuo FC.  2016.  Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies.. J Mol Diagn. 18(4):507-15.
Kluk MJ, R Lindsley C, Aster JC, Lindeman NI, Szeto D, Hall D, Kuo FC.  2016.  Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies.. J Mol Diagn. 18(4):507-15.
2015
Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, Chandramohan R, Liu ZYu, Won HH, Scott SN et al..  2015.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.. J Mol Diagn. 17(3):251-64.
Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, Chandramohan R, Liu ZYu, Won HH, Scott SN et al..  2015.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.. J Mol Diagn. 17(3):251-64.
Kluk MJ, Abo RP, Brown RD, Kuo FC, Dal Cin P, Pozdnyakova O, Morgan EA, Lindeman NI, DeAngelo DJ, Aster JC.  2015.  Myeloid neoplasm demonstrating a STAT5B-RARA rearrangement and genetic alterations associated with all-trans retinoic acid resistance identified by a custom next-generation sequencing assay.. Cold Spring Harb Mol Case Stud. 1(1):a000307.